This is a non-core endpoint: only basic statistics are computed.
Carcinoma in situ of prostate
CD2_INSITU_PROSTATE
Grade III Prostatic Intraepithelial Neoplasia: High grade prostatic intraepithelial neoplasia characterized by the presence of severe architectural and cytologic abnormalities.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleonly males |
244368 |
2. Check conditions
|
220998 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
3 out of 7 registries used, show all original rules. |
175 |
4. Check minimum number of eventsNone |
175 |
5. Include endpointsNone |
175 |
6. Filter based on genotype QC (FinnGen only) |
158 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF9
- Parent code in ICD-10
- D07
- Name in latin
- Carcinoma in situ oculi
Carcinoma in situ of prostate
based on the number of shared cases.
Similar with more cases:
Similar with less cases:
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 158 | - | 158 |
| Unadjusted period prevalence (%) | 0.07 | - | 0.07 |
| Median age at first event (years) | 68.14 | - | 68.14 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 164
- Matched controls
- 1640
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
8148/2-C61.9
ICD-O-3
Glandular intraepithelial neoplasia, high grade of prostate gland
+∞
178.3
137
*
KE1AT
NOMESCO Finland
Biopsy of prostata with ultrasoudnguidance
11.0
53.1
82
137
R74.8
ICD-10 Finland
Abnormal levels of other serum enzymes
8.2
37.4
67
127
R86.0
ICD-10 Finland
Abnormal findings in specimens from male genital organs, abnormal level of enzymes
11.9
34.1
39
42
N40
ICD-10 Finland
Hyperplasia of prostate
6.7
24.2
133
639
8140/2-C61.9
ICD-O-3
Adenocarcinoma in situ, NOS, of prostate gland
+∞
23.5
22
*
KE1BE
NOMESCO Finland
Rectal ultrasound examinaiton of prostata
4.6
19.6
67
214
KC1EE
NOMESCO Finland
Ultrasound measurement of residual urine
4.3
19.2
82
309
XKD00
NOMESCO Finland
Uroflowmetry
4.0
17.1
86
357
TKE00
NOMESCO Finland
Needle biopsy of prostate
5.2
14.1
33
76
KEB00
NOMESCO Finland
Biopsy of prostate
11.7
10.1
18
17
G04CB02
ATC
dutasteride; oral
3.2
9.7
49
193
G04CA52
ATC
tamsulosin and dutasteride; systemic
3.0
9.6
60
267
8140/3-C61.9
ICD-O-3
Adenocarcinoma, NOS, of prostate gland
0.0
8.6
*
204
G04CA02
ATC
tamsulosin; oral
2.4
7.0
99
633
J01MA02
ATC
ciprofloxacin; systemic
2.3
6.4
84
515
R33
ICD-10 Finland
Retention of urine
2.8
6.2
35
144
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
131
733
4.91
16.79
6.2
3.4
1.02
0.78
ug/l
3.32
118
491
145
977
5.18
12.15
8.5
4.9
17.63
21.79
%
6.93
124
501
90
489
2.86
10.00
4.6
3.2
0.45
0.49
e6/l
0.05
74
368
81
432
2.73
9.10
4.4
3.4
0.00
0.00
estimate
-0.00
32
140
101
604
2.75
9.00
4.8
3.8
0.00
0.02
estimate
0.50
31
153
63
302
2.76
8.64
3.8
2.9
0.79
0.88
e6/l
0.17
41
170
60
281
2.79
8.60
4.0
3.1
0.29
0.54
e6/l
1.41
38
151
115
762
2.70
7.92
4.8
3.8
0.00
0.00
estimate
-0.00
39
175
115
771
2.65
7.58
4.9
3.8
0.00
0.00
estimate
-0.00
42
177
116
781
2.66
7.57
4.8
3.8
0.00
0.03
estimate
0.50
39
155
154
1219
5.32
7.44
9.9
5.8
5.89
2.44
ug/l
12.95
149
1100
71
455
1.99
4.36
5.1
3.8
0.00
0.03
estimate
0.78
34
157
158
1427
3.93
3.86
6.4
6.6
2.49
2.48
mmol/l
0.07
148
1320
155
1385
3.17
3.74
19.4
19.5
30.76
28.54
mg/l
0.24
145
1184
158
1465
3.14
2.60
25.0
24.0
4.03
4.04
mmol/l
0.33
158
1449
158
1462
3.20
2.59
24.8
23.8
139.70
139.55
mmol/l
0.29
158
1447
153
1383
2.58
2.52
5.9
5.8
6.18
6.24
mmol/l
0.25
145
1261
151
1359
2.40
2.47
4.8
4.8
1.35
1.33
mmol/l
0.09
141
1245
153
1393
2.47
2.29
5.8
5.8
4.25
4.25
mmol/l
0.01
143
1294
127
1091
1.73
2.24
4.4
4.3
11.81
12.79
mm/h
0.29
120
1022
32
193
1.82
2.21
4.6
3.2
—
—
—
0
0
28
162
1.88
2.20
3.6
3.3
4.30
4.57
kpa
0.34
28
156
96
774
1.58
2.15
6.3
8.6
1.21
1.19
mmol/l
0.60
75
684
152
1392
2.26
2.03
5.8
5.7
1.28
1.30
mmol/l
0.36
142
1281
13
59
2.31
1.90
2.8
2.8
1.56
1.65
mg/l
0.18
13
53
140
1260
1.76
1.79
4.3
4.2
2.00
2.10
mu/l
0.39
132
1129
30
191
1.70
1.73
5.1
4.1
5.85
5.66
kpa
0.53
30
186
113
984
1.48
1.49
3.5
3.2
14.97
14.82
pmol/l
0.24
102
873
7
28
2.56
1.47
1.7
1.4
—
—
—
0
0
36
253
1.54
1.40
6.9
7.0
0.97
1.03
mmol/l
0.71
36
246
83
689
1.41
1.38
1.9
2.2
88.66
92.12
pmol/l
0.36
51
406
15
85
1.84
1.28
3.0
1.9
41.73
42.84
nmol/l
0.08
15
79
6
26
2.36
1.20
1.3
1.4
—
—
—
0
0
84
713
1.37
1.16
4.0
4.3
50.42
45.57
ng/l
0.09
69
586
40
304
1.42
1.06
1.5
2.0
31.98
29.16
s
2.15
40
297
96
840
1.34
1.06
9.1
10.4
4.38
4.37
e9/l
0.01
83
735
43
335
1.38
0.99
3.9
4.1
1.02
1.02
kg/l
0.18
37
226
51
415
1.33
0.89
1.9
2.1
2.85
3.02
mg/l
0.26
42
361
19
133
1.48
0.78
1.3
1.3
—
—
—
0
0
106
964
1.28
0.77
4.8
5.7
7.18
7.02
mmol/l
0.29
97
934
18
125
1.49
0.76
2.4
2.6
56.00
61.42
ml/min/173m2
—
7
62
78
688
1.26
0.72
2.4
2.5
—
—
—
0
0
7
118
0.58
0.71
1.4
1.7
—
—
—
0
0
11
70
1.61
0.67
1.0
2.6
50.70
161.12
mg/l
—
6
57
11
70
1.61
0.67
1.0
2.7
48.77
42.02
mg/l
—
6
59
5
28
1.81
0.66
1.0
1.2
3.82
3.78
mmol/l
—
5
28
13
87
1.54
0.65
1.2
1.2
200.12
504.04
u/ml
0.78
13
79
54
463
1.25
0.62
2.9
3.2
395.76
376.09
umol/l
0.57
45
403
5
30
1.69
0.62
2.2
2.9
11.48
10.26
pmol/l
—
5
30
80
717
1.23
0.61
3.0
2.9
—
—
estimate
—
0
0
56
484
1.24
0.60
1.8
1.7
19.73
19.03
nmol/l
0.11
49
398
30
240
1.31
0.59
4.2
4.2
400.87
243.72
u/l
0.78
30
230
22
168
1.36
0.59
5.7
8.7
1.37
1.43
mmol/l
0.11
22
168
8
55
1.48
0.57
1.8
1.5
—
—
—
0
0
19
145
1.35
0.51
2.6
2.1
461.79
381.60
nmol/l
0.59
19
133
101
939
1.20
0.49
2.8
4.1
58.52
66.87
u/l
0.26
96
881
79
719
1.19
0.49
5.3
6.0
34.56
34.65
g/l
0.04
73
684
67
601
1.19
0.48
2.8
3.5
2220.18
1490.45
ng/l
0.54
61
512
69
623
1.19
0.46
4.3
4.5
6.59
11.54
mg/mmol
1.09
51
436
5
32
1.58
0.42
1.0
1.4
—
—
—
0
0
0
15
0.00
0.41
0.0
1.1
—
—
—
0
0
0
19
0.00
0.39
0.0
2.3
—
—
—
0
0
0
19
0.00
0.39
0.0
1.1
—
—
—
0
0
0
19
0.00
0.39
0.0
1.1
—
25.60
—
0
5
38
333
1.18
0.35
1.3
1.7
1.84
1.84
mg/l
0.00
30
268
6
45
1.35
0.34
1.2
1.0
—
—
—
0
0
13
103
1.28
0.29
7.1
3.6
23.75
23.78
mmol/l
0.01
13
103
8
63
1.28
0.28
4.5
3.9
4.55
4.32
pmol/l
—
8
56
64
599
1.11
0.23
2.1
2.0
1.52
1.35
mmol/l
0.94
50
495
0
11
0.00
0.21
0.0
2.3
—
—
—
0
0
0
11
0.00
0.21
0.0
5.9
—
89.82
—
0
11
0
10
0.00
0.21
0.0
3.0
—
100.80
—
0
10
0
10
0.00
0.21
0.0
1.0
—
11.99
—
0
10
0
10
0.00
0.21
0.0
3.1
—
1.10
—
0
10
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
12
0.00
0.21
0.0
1.4
—
—
—
0
0
0
12
0.00
0.21
0.0
1.4
—
—
—
0
0
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
1.5
—
—
—
0
0
0
13
0.00
0.21
0.0
2.2
—
—
—
0
0
0
13
0.00
0.21
0.0
1.5
—
—
—
0
0
0
13
0.00
0.21
0.0
1.0
—
—
—
0
0
0
14
0.00
0.20
0.0
1.9
—
13.93
—
0
14
6
49
1.23
0.20
1.0
1.3
—
—
—
0
0
11
131
0.83
0.18
2.5
3.6
181.55
230.37
ng/l
0.29
11
116
20
178
1.14
0.16
1.3
1.3
1.28
20.88
u/ml
—
8
66
17
187
0.90
0.10
9.8
8.4
—
—
—
0
0
10
114
0.87
0.10
2.0
1.8
—
—
—
0
0
6
55
1.09
0.09
1.0
1.5
—
—
—
0
0
6
55
1.09
0.09
1.3
1.5
—
—
—
0
0
7
80
0.87
0.07
2.4
3.6
13797.76
1425.21
u/ml
—
7
63
60
586
1.04
0.05
2.3
2.3
77.63
72.68
nmol/l
0.73
54
513
38
392
0.96
0.04
2.3
2.5
—
—
—
0
0
23
220
1.05
0.04
1.7
2.2
—
—
—
0
0
30
292
1.03
0.02
2.1
1.7
1565.08
1216.39
nmol/l
1.10
24
226
10
96
1.04
0.00
1.2
1.5
—
—
—
0
0
15
146
1.03
0.00
1.5
1.5
—
—
—
0
0
28
276
1.02
0.00
8.5
7.6
104.11
104.24
mmol/l
0.05
28
276
20
201
0.99
0.00
1.3
1.2
9.84
40.57
iu/ml
—
5
59
27
271
1.00
0.00
1.4
1.2
14.25
0.97
u/ml
—
8
80
31
309
1.00
0.00
1.5
2.1
—
—
—
0
0
23
235
0.98
0.00
1.7
2.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.6
—
—
—
0
0
7
77
0.91
-0.00
3.9
3.5
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
2.4
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
2.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
6.4
—
4.68
—
0
5
0
7
0.00
-0.00
0.0
2.6
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
6.4
—
9.98
—
0
5
(40770918) von Willebrand factor (vWf).activity actual/normal in Platelet poor plasma by Immunoassay
0
6
0.00
-0.00
0.0
1.0
—
159.17
—
0
6
0
7
0.00
-0.00
0.0
1.6
—
3.42
—
0
7
0
5
0.00
-0.00
0.0
2.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
1170.40
—
0
5
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.5
—
—
—
0
0
(3011547) Coagulation factor VII activity actual/normal in Platelet poor plasma by Coagulation assay
0
5
0.00
-0.00
0.0
1.2
—
88.20
—
0
5
0
7
0.00
-0.00
0.0
2.6
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.9
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
6.7
—
6.14
—
0
7
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
2.6
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
2.7
—
37.50
—
0
6
0
6
0.00
-0.00
0.0
7.7
—
11.50
—
0
6
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
8
0.00
-0.00
0.0
2.3
—
—
—
0
0
0
7
0.00
-0.00
0.0
2.7
—
13.14
—
0
7
0
7
0.00
-0.00
0.0
2.4
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: CD2_INSITU_PROSTATE – Carcinoma in situ of prostate
GWS hits: 2
This endpoint is excluded from FinRegistry analyses (omitted endpoint).